Source BioScience PLC Form 8 (OPD) Source BioScience plc (5812B)
17 Junho 2016 - 8:55AM
UK Regulatory
TIDMSBS
RNS Number : 5812B
Source BioScience PLC
17 June 2016
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Source BioScience plc
--------------------------------------------------------------------------------------------- ----------------------
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
--------------------------------------------------------------------------------------------- ----------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Source BioScience plc
Use a separate form for each offeror/offeree
--------------------------------------------------------------------------------------------- ----------------------
(d) Is the discloser the offeror or the offeree? Offeree
--------------------------------------------------------------------------------------------- ----------------------
(e) Date position held: 16 June 2016
The latest practicable date prior to the disclosure
--------------------------------------------------------------------------------------------- ----------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect N/A
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
--------------------------------------------------------------------------------------------- ----------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security:
----------------------------------------------------------------------------------- --------------------------------
Interests Short positions
----------------------------------------------------------------------------------- ------------ ------------------
Number % Number %
----------------------------------------------------------------------------------- -------- ------------- ---
(1) Relevant securities owned and/or controlled: Nil - Nil -
----------------------------------------------------------------------------------- -------- ------------- ---
(2) Cash-settled derivatives: Nil - Nil -
----------------------------------------------------------------------------------- -------- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: Nil - Nil -
----------------------------------------------------------------------------------- -------- ------------- ---
Nil - Nil -
TOTAL:
----------------------------------------------------------------------------------- -------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: None
---------------------------------------------------------------------------- -----
Details, including nature of the rights concerned and relevant percentages: None
---------------------------------------------------------------------------- -----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
----------------------------------------------------------------------------------------------
3(a) Beneficial holdings of the Directors of Source BioScience plc in its Ordinary Shares
Director Number of Ordinary Percentage of
Shares total issued
share capital
(%)
----------------- ------------------- ---------------
Laurie Turnbull 2,750,000 0.79
Dr Nick Ash 500,000 0.14
Dr Nick Leaves 1,028,557 0.29
----------------- ------------------- ---------------
3(b) Interests of the Directors in Source BioScience plc Ordinary Shares under the Source
BioScience Executive Share Option Scheme and the Source BioScience 2015 Long Term Incentive
Plan
Director Maximum Date of First Last exercisable Option
number Grant exercisable date price
of Ordinary date (pence)
Shares
awarded
-------------- ------------- -------- ------------- ----------------- ---------
Laurie 31 Mar 31 Mar 30 mar
Turnbull 500,000 2008 2011 2018 7.88p
26 Apr 26 Apr 25 Apr
400,000 2010 2013 2020 8.25p
-------------- ------------- -------- ------------- ----------------- ---------
Dr Nick 31 Mar 31 Mar 30 Mar
Ash 500,000 2008 2011 2018 7.88p
31 Mar 31 Mar 30 Mar
400,000 2009 2012 2019 4.63p
26 Apr 26 Apr 25 Apr
400,000 2010 2013 2020 8.25p
27 Sep 27 Sep 26 Sep
600,000 2013 2016 2023 9.38p
21 Oct 21 Oct 20 Oct
1,500,000 2013 2016 2023 9.50p
21 Oct 21 Oct 20 Oct
1,500,000 2013 2016 2023 9.50p
21 Oct 21 Oct 20 Oct
500,000 2013 2017 2024 9.50p
3,821,538 25 Jun 15 Mar 25 Jun nil
2015 2019 2025
-------------- ------------- -------- ------------- ----------------- ---------
Dr Nick 31 Mar 31 Mar 30 Mar
Leaves 200,000 2008 2011 2018 7.88p
31 Mar 31 Mar 30 Mar
300,000 2009 2012 2019 4.63p
26 Apr 26 Apr 25 Apr
300,000 2010 2013 2020 8.25p
24 Apr 24 Apr 23 Apr
300,000 2011 2014 2021 6.25p
27 Sep 27 Sep 26 Sep
400,000 2013 2016 2023 9.38p
21 Oct 21 Oct 20 Oct
1,000,000 2013 2016 2023 9.50p
21 Oct 21 Oct 20 Oct
1,600,000 2013 2016 2023 9.50p
21 Oct 21 Oct 20 Oct
400,000 2013 2017 2024 9.50p
3,108,462 25 Jun 15 Mar 25 Jun nil
2015 2019 2025
-------------- ------------- -------- ------------- ----------------- ---------
Tim Metcalfe 2,769,231 25 Jun 15 Mar 25 Jun nil
2015 2019 2025
-------------- ------------- -------- ------------- ----------------- ---------
----------------------------------------------------------------------------------------------
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
------------------------------------------------------------------------------------------------
None
------------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
----------------------------------------------------------------------------------------------
None
----------------------------------------------------------------------------------------------
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
------------------------------------- ---
Supplemental Form 8 (SBL) NO
------------------------------------- ---
Date of disclosure: 17 June 2016
--------------------- --------------------
Contact name: Dr Nick Ash
--------------------- --------------------
Telephone number: +44 (0)115 973 9010
--------------------- --------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FEEUBVARNOANAAR
(END) Dow Jones Newswires
June 17, 2016 07:55 ET (11:55 GMT)
Source Bioscience (LSE:SBS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Source Bioscience (LSE:SBS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
